Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á¶Á÷ÇÐÀûÀ¸·Î È®ÁøµÈ µÎ°³³» ¹è¾ÆÁ¾ÀÇ Àüº¸Á¶È­Çпä¹ý ÈÄ ¹æ»ç¼±Ä¡·áÀÇ ¼ºÀû - ¿¹ºñÀû °á°ú Efficacy of Neoadjuvant Chemotherapy and Radiotherapy for the Histology-confirmed Intracranial Germinoma - Preliminary Report

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2002³â 20±Ç 2È£ p.93 ~ 99
¼Ò¼Ó »ó¼¼Á¤º¸
³ë¿µÁÖ/Young Ju Noh ±èÇÐÀç/Çã´ë¼®/½ÅÈñ¿µ/±èÀÏÇÑ/Hak Jae Kim/Dae Seog Heo/Hee Yung Shin/Il Han Kim

Abstract

¸ñÀû: µÎ°³³» ¹è¾ÆÁ¾Àº ¹æ»ç¼±Ä¡·á ´Üµ¶À¸·Îµµ ¿ÏÄ¡À²ÀÌ ³ôÀº Á¾¾çÀ̳ª ¹æ»ç¼±Ä¡·á·Î ÀÎÇÑ ºÎÀÛ¿ëÀÇ °¨¼Ò¸¦ À§ÇØ ÇöÀç ¼­¿ï´ëÇб³ º´¿ø¿¡¼­´Â Àüº¸Á¶È­Çпä¹ý ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ÇÏ°í ÀÖÀ¸¸ç ÀÌ È¯ÀÚµéÀÇ Ä¡·á ¼ºÀû°ú ºÎÀÛ¿ëÀ» ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1995³â¿¡¼­ 2001³â±îÁö Ä¡·á¸¦ ¹ÞÀº µÎ°³³» ¹è¾ÆÁ¾À¸·Î Á¶Á÷ÇÐÀûÀ¸·Î Áø´ÜµÈ 18¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. 12¸íÀº BEP (bleomycin, VP-16, cisplatin) Ç×¾ÏÄ¡·á, 5¸íÀº 9921A (cisplatin, cyclophosphamide, VP-16, vincristine) Ç×¾ÏÄ¡·á,
1¸íÀº
EP (VP-16, cisplatin) Ç×¾ÏÄ¡·á¸¦ ¹Þ¾Ò°í 5¸íÀº µÎ°³Ã´¼öÁ¶»ç, 1¸íÀº µÎ°³¹æ»ç¼±Á¶»ç, 12¸íÀº Á¾¾ç ºÎÀ§¿¡¸¸ ¹æ»ç¼±Ä¡·á¸¦ ¹Þ¾Ò´Ù. ¿ø¹ß Á¾¾ç¿¡ Á¶»çµÈ ¹æ»ç¼±·®Àº 39.6¿¡¼­ 54 §í¿´´Ù.

°á°ú: ³²ÀÚ´Â 16¸í, ¿©ÀÚ´Â 2¸íÀ̾ú°í Áß°£ ³ªÀÌ´Â 16¼¼¿´´Ù. ÀÚ±â°ø¸í¿µ»ó »ó 12¸íÀº ¼Û°úü¿¡, °¢°¢ 1¸í¿¡¼­ ¾È»ó, ½Ã»ó, ´ë³ú±âÀúÇÙ¿¡ ¿ø¹ß¼º Á¾±«°¡ ÀÖ¾ú°í 3¸í¿¡¼­ ´Ù¹ß¼º Á¾±«°¡ ÀÖ¾ú´Ù. 6¸íÀº ³ú½Ç ³» ÀüÀÌ ¼Ò°ßÀÌ º¸¿´°í 3¸íÀº ³úôÃß¾×°Ë»ç »ó Á¾¾ç
¼¼Æ÷°¡
°üÂûµÇ¾ú°í 2¸í¿¡¼­´Â ô¼ö ÀÚ±â°ø¸í¿µ»ó¿¡¼­ ÀüÀÌ ¼Ò°ßÀÌ ÀÖ¾ú´Ù. Á¾¾çÁöÇ¥°Ë»ç »ó 1¸í¿¡¼­ ¥â-human chorionic gonadotropinÀÇ ¼öÄ¡°¡ 44 §¢U/§¢·Î »ó½ÂµÇ¾î ÀÖ¾ú´Ù. Ç×¾ÏÄ¡·á ÈÄ 5¸íÀº ¿ÏÀü °üÇØ, 12¸íÀº ºÎºÐ °üÇظ¦ º¸¿´°í, 1¸íÀº ¹ÝÀÀÀÌ ¾ø¾ú´Ù. ÇöÀç Áß¾Ó
̧˞
±â°£
20°³¿ù·Î 17¸íÀº ¹«º´ »óÅ·Π°üÂûµÇ°í ÀÖ°í 1¸íÀº bleomycinÀ¸·Î ÀÎÇÑ °ÍÀ¸·Î ÃßÁ¤µÇ´Â ÆóÀÇ ºÎÀÛ¿ëÀ¸·Î »ç¸ÁÇÏ¿´´Ù. »ç¸ÁÇÑ È¯ÀÚ¸¦ Á¦¿ÜÇÑ ´Ù¸¥ ȯÀÚµéÀº ¹æ»ç¼±Ä¡·á ÈÄ ¸ðµÎ ¿ÏÀü °üÇØ »óÅÂÀÌ´Ù. 6¸í¿¡¼­ ¹éÇ÷±¸ °¨¼Ò·Î ÀÎÇÑ °¨¿°ÀÌ ¹ß»ýÇÏ¿´À¸¸ç 3¡­4µµÀÇ
Ç÷¾×ÇÐÀû
ºÎÀÛ¿ëÀÌ 11¸í¿¡¼­ ¹ß»ýÇÏ¿´´Ù. ¹æ»ç¼±Á¶»ç Áß µÎ°³Ã´¼öÁ¶»ç¸¦ ¹ÞÀº 5¸íÀÇ È¯ÀÚ¸¦ Á¦¿ÜÇÑ ³ª¸ÓÁö ȯÀÚ¿¡¼­´Â 2µµ ÀÌ»óÀÇ ºÎÀÛ¿ëÀº º¸ÀÌÁö ¾Ê¾Ò´Ù.

°á·Ð: ¼­¿ï´ëÇб³º´¿ø¿¡¼­ÀÇ Àüº¸Á¶È­Çпä¹ý ÈÄ ¹æ»ç¼±Ä¡·á´Â ±âÁ¸ÀÇ º¸°í¿Í ¸¶Âù°¡Áö·Î ³ôÀº °üÇØÀ²À» º¸ÀÌ°í ÀÖ°í Ç×¾ÏÄ¡·á·Î ÀÎÇÑ Ä¡·á ÁßÀ̳ª Ä¡·á ÈÄÀÇ ºÎÀÛ¿ëÀÇ Á¤µµ¿Í ºóµµ´Â ´Ù¸¥ º¸°í¿Í ºñ½ÁÇÏ¿´´Ù. ¹æ»ç¼±À̳ª Ç×¾ÏÄ¡·á·Î ÀÎÇÑ ¸¸¼º ºÎÀÛ¿ë¿¡
´ëÇؼ­´Â
Á»´õ °üÂûÀÌ ÇÊ¿äÇϸç ÀÌ °á°ú°¡ ³ª¿Â ÈÄ¿¡ µÎ°³³» ¹è¾ÆÁ¾¿¡¼­ °¡Àå ÀûÀýÇÑ Ä¡·á¿¡ ´ëÇØ °á·ÐÀ» ³»¸± ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀδÙ.

Purpose: We intended to decrease late CNS reaction after radical radiotherapy for an intracranial germinoma by using combined neoadjuvant chemotherapy and involved-field radiotherapy. The efficacy in terms of its acute toxicity and
short-term
relapse patterns was analyzed.

Materials and Methods: Eighteen patients were treated with combined neoadjuvant chemotherapy and radiotherapy between 1995 and 2001. The chemotherapy regimen used was the Children's Cancer Group (CCG) 9921A (cisplatin, cyclophosphamide,
VP-16,
vincristine) for 5 patients younger than 16 years, BEP (bleomycin, VP-16, cisplatin) for 12 patients, and EP (VP-16, cisplatin) for 1 patient. The radiotherapy covered the whole craniospinal axis for 5 patients, the whole brain for 1, and the
partial
brain (involved field) for 12. the primary lesion received tumour doses between 3,960 and 5,400 c§í.

Results: The male to female ratio was 16:2 and the median age was 16 years old. The tumors were located in the pineal gland in 12 patients, in the suprasellar region in 1, in the basal ganglia in 1, in the thalamus in 1. Three patients had
multiple lesions and ventricular seedings were shown at MRI. In 3 patients, tumor cells were detected in the cerebrospinal fluid and MRI detected a spinal seeding in 2 patients. The response to neoadjuvant chemotherapy was complete remission in 5
patients, partial remission in 12, and no response in 1. However, after radiotherapy, all except 1 patient experienced complete remission. The toxicity during or after chemotherapy greater than or equal to grade ¥² was remarkable; hematologic
toxicity
was observed in 11 patients, liver toxicity in none, kidney toxicity in none, and gastrointestinal toxicity in one. One patient suffered from bleomycin-induced pneumonitis. Radiotherapy was therefore stopped and the patient eventually died of
respiratory failure. The other 17 are alive without any evidence of disease or relapse during an average of 20 months follow-up.

Conclusion: A high response rate and disease control was experienced, which was the same as observed other studies and the morbidity from chemotherapy-induced toxicity was similar. With these results, the results from adjuvant chemotherapy
and
involved-field radiotherapy cannot be concluded to be equal to those from extended-field radiotherapy. The long term follow-up study on later complications are required in order to draw definite conclusions on the optimal management with minimum
side
effects.

Å°¿öµå

µÎ°³³» ¹è¾ÆÁ¾; Àüº¸Á¶È­Çпä¹ý; ¹æ»ç¼±Ä¡·á; Intracranial germinoma; Neoadjuvant chemotherapy; Radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS